Ignite Creation Date:
2024-05-06 @ 8:17 PM
Last Modification Date:
2024-10-26 @ 3:24 PM
Study NCT ID:
NCT06326528
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-03-22
First Post:
2024-03-09
Brief Title:
SGLT2 Inhibitors and Perioperative Period
Sponsor:
Assiut University
Organization:
Assiut University
Study Overview
Official Title:
Short Term Outcome of SGLT2 Inhibitors on Patients Who Undergo Cardiac Surgery in Perioperative Period
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The expanded use of SGLT2 inhibitors motivates us to assess the role of SGLT2 inhibitors in perioperative period on patients who will undergo cardiac surgery in Assiut University
Detailed Description:
With over 50 million cases of heart failure worldwide heart failure is one of the most serious health issues facing humanity Heart failure patients still have an extremely poor prognosis and quality of life even with advancements in heart failure treatment It continues to be the most common cause of hospitalization in elderly
A substantial number of theories have been proposed to explain the beneficial effects of SGLT2 inhibitors These include blood pressure lowering increasing diuresisnatriuresis improving cardiac energy metabolism preventing inflammation weight loss improving glucose control inhibiting the sympathetic nervous system preventing adverse cardiac remodeling preventing ischemiareperfusion injury inhibiting the cardiac NaH exchanger inhibiting SGLT1 reducing hyperuricemia increasing autophagy and lysosomal degradation decreasing epicardial fat mass increasing erythropoietin EPO levels increasing circulating provascular progenitor cells decreasing oxidative stress and improving vascular function
In addition to lowering blood sugar several large trials also have demonstrated cardiovascular and renal benefits in patients with T2DM Surprisingly recent data also suggest that SGLT-2 inhibitors may improve cardiovascular and renal outcomes in patients without diabetes leading to expanded indications for their use
A substantial number of theories have been proposed to explain the beneficial effects of SGLT2 inhibitors These include blood pressure lowering increasing diuresisnatriuresis improving cardiac energy metabolism preventing inflammation weight loss improving glucose control inhibiting the sympathetic nervous system preventing adverse cardiac remodeling preventing ischemiareperfusion injury inhibiting the cardiac NaH exchanger inhibiting SGLT1 reducing hyperuricemia increasing autophagy and lysosomal degradation decreasing epicardial fat mass increasing erythropoietin EPO levels increasing circulating provascular progenitor cells decreasing oxidative stress and improving vascular function
In addition to lowering blood sugar several large trials also have demonstrated cardiovascular and renal benefits in patients with T2DM Surprisingly recent data also suggest that SGLT-2 inhibitors may improve cardiovascular and renal outcomes in patients without diabetes leading to expanded indications for their use
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None